What's Happening?
Latham & Watkins LLP has provided legal representation for the private credit funds involved in the partnership between Apex Infusion and SkyKnight Capital. Apex Infusion, a prominent provider of omnichannel infusion services, has entered into a definitive
agreement with SkyKnight Capital, a private equity firm known for building industry-leading businesses. The partnership aims to drive Apex's growth, with its clinician-led management team retaining a significant ownership stake and continuing to lead the business. FFL Partners will also remain a minority investor. The transaction is subject to customary closing conditions, including regulatory approvals.
Why It's Important?
This partnership is significant as it highlights the ongoing trend of private equity firms investing in healthcare services, particularly those with innovative service delivery models like Apex Infusion. The involvement of Latham & Watkins underscores the complexity and importance of legal guidance in structuring such deals. The partnership is expected to enhance Apex's growth potential, allowing it to expand its services and market reach. For SkyKnight Capital, this investment represents an opportunity to leverage its expertise in scaling businesses, potentially leading to increased returns for its investors.
What's Next?
The partnership is pending regulatory approvals, which are standard in such transactions. Once approved, Apex Infusion is expected to implement growth strategies facilitated by the new capital and expertise from SkyKnight Capital. This could include expanding its service offerings, entering new markets, or enhancing its technological capabilities. Stakeholders will be closely monitoring the regulatory process and the subsequent strategic moves by Apex Infusion to assess the partnership's impact on the healthcare services market.
